US Stock MarketDetailed Quotes

CRSP CRISPR Therapeutics

Watchlist
  • 50.760
  • +4.370+9.42%
Close Nov 1 16:00 ET
  • 50.987
  • +0.227+0.45%
Post 19:55 ET
4.32BMarket Cap-15862P/E (TTM)

CRISPR Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
28.27%-95.58M
1,147.32%109.75M
47.48%-260.38M
15.23%-96.07M
62.12%-39.86M
6.14%-133.25M
106.51%8.8M
-191.98%-495.74M
-31.72%-113.33M
-29.37%-105.22M
Net income from continuing operations
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
-37.27%-174.55M
Depreciation and amortization
-2.34%4.85M
-4.32%4.83M
-17.93%19.84M
-16.18%4.9M
-1.85%4.93M
-31.75%4.96M
-16.36%5.05M
34.64%24.17M
-6.63%5.85M
-5.75%5.02M
Other non cash items
-159.63%-8.18M
-765.33%-8.39M
-212.63%-14.05M
-2,276.26%-4.77M
-299.96%-5.16M
-188.21%-3.15M
-115.89%-969K
-11.62%12.47M
-95.33%219K
-48.43%2.58M
Change In working capital
113.27%10.49M
470.33%210.49M
-1,075.49%-193.59M
-545.02%-203.97M
41.34%52.56M
-1,066.16%-79.08M
505.53%36.91M
-26.11%19.85M
-271.01%-31.62M
299.96%37.19M
-Change in receivables
--0
--200M
-65,673.77%-200M
-408,263.27%-200M
411,664.71%70M
-91,009.09%-70M
--0
289.44%305K
132.03%49K
950.00%17K
-Change in prepaid assets
-39.98%2.35M
-75.51%2.95M
1,353.00%23.22M
218.05%6.45M
-83.76%817K
251.69%3.91M
161.11%12.04M
111.49%1.6M
-212.36%-5.46M
154.06%5.03M
-Change in payables and accrued expense
180.17%9.28M
-62.55%9.44M
-492.08%-20.25M
70.44%-9.19M
-188.32%-24.69M
-216.72%-11.58M
1,660.27%25.21M
-86.23%5.16M
-236.50%-31.1M
2,040.74%27.96M
-Change in other current liabilities
112.70%40K
-154.12%-432K
107.23%110K
7.80%705K
89.29%-110K
68.31%-315K
-10.39%-170K
71.33%-1.52M
-44.48%654K
-67.54%-1.03M
-Change in other working capital
-7.18%-1.18M
-730.51%-1.47M
-76.69%3.33M
-145.76%-1.94M
25.68%6.55M
-162.43%-1.1M
-105.72%-177K
63.92%14.3M
141.61%4.24M
-70.91%5.21M
Cash from discontinued investing activities
Operating cash flow
28.27%-95.58M
1,147.32%109.75M
47.48%-260.38M
15.23%-96.07M
62.12%-39.86M
6.14%-133.25M
106.51%8.8M
-191.98%-495.74M
-31.72%-113.33M
-29.37%-105.22M
Investing cash flow
Cash flow from continuing investing activities
-158.50%-126.91M
-183.00%-97.8M
244.84%374.65M
53.60%-81.45M
38.74%121.35M
486.87%216.92M
202.89%117.83M
75.02%-258.66M
-1,913.91%-175.53M
115.48%87.46M
Net PPE purchase and sale
80.11%-707K
76.43%-721K
74.53%-9.47M
88.08%-738K
64.80%-2.12M
63.08%-3.56M
80.07%-3.06M
54.49%-37.19M
32.58%-6.19M
83.76%-6.02M
Net intangibles purchase and sale
----
----
---2.5M
--0
---1M
----
----
--0
--0
--0
Net investment purchase and sale
-156.85%-126.2M
-180.30%-97.08M
274.57%386.62M
52.34%-80.72M
33.15%124.47M
577.97%221.98M
221.91%120.89M
76.78%-221.47M
-36,361.46%-169.34M
117.70%93.48M
Cash from discontinued investing activities
Investing cash flow
-158.50%-126.91M
-183.00%-97.8M
244.84%374.65M
53.60%-81.45M
38.74%121.35M
486.87%216.92M
202.89%117.83M
75.02%-258.66M
-1,913.91%-175.53M
115.48%87.46M
Financing cash flow
Cash flow from continuing financing activities
-102.78%-466K
5,561.25%305.93M
62.38%62.66M
1,471.39%38.94M
-89.70%1.56M
61.93%16.77M
-49.25%5.4M
-84.62%38.59M
-60.66%2.48M
47.98%15.11M
Net common stock issuance
---1.01M
--280.75M
3,273.30%32.72M
--32.72M
--0
--0
--0
-99.55%970K
--0
----
Proceeds from stock option exercised by employees
-96.74%546K
366.12%25.19M
-20.41%29.94M
150.93%6.22M
-89.00%1.56M
61.93%16.77M
-49.25%5.4M
-0.15%37.62M
-60.66%2.48M
38.48%14.14M
Cash from discontinued financing activities
Financing cash flow
-102.78%-466K
5,561.25%305.93M
62.38%62.66M
1,471.39%38.94M
-89.70%1.56M
61.93%16.77M
-49.25%5.4M
-84.62%38.59M
-60.66%2.48M
47.98%15.11M
Net cash flow
Beginning cash position
101.88%718.94M
79.00%401.07M
-76.16%224.06M
5.74%539.6M
-11.01%456.6M
-49.18%356.12M
-76.16%224.06M
-20.71%939.94M
-50.38%510.33M
-69.18%513.07M
Current changes in cash
-321.97%-222.95M
140.76%317.89M
124.72%176.94M
51.61%-138.59M
3,243.38%83.05M
153.52%100.44M
155.22%132.03M
-191.55%-715.8M
-223.76%-286.38M
99.58%-2.64M
Effect of exchange rate changes
-92.86%2K
-134.38%-11K
191.25%73K
-46.96%61K
52.00%-48K
141.18%28K
218.52%32K
-627.27%-80K
3,733.33%115K
-316.67%-100K
End cash Position
8.63%495.99M
101.88%718.94M
79.00%401.07M
79.00%401.07M
5.74%539.6M
-11.01%456.6M
-49.18%356.12M
-76.16%224.06M
-76.16%224.06M
-50.38%510.33M
Free cash flow
30.38%-96.29M
1,799.49%109.03M
48.90%-272.35M
19.00%-96.81M
61.37%-42.97M
8.76%-138.3M
103.81%5.74M
-216.55%-532.93M
-25.52%-119.52M
6.03%-111.24M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
--
--
Unqualified Opinion
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 28.27%-95.58M1,147.32%109.75M47.48%-260.38M15.23%-96.07M62.12%-39.86M6.14%-133.25M106.51%8.8M-191.98%-495.74M-31.72%-113.33M-29.37%-105.22M
Net income from continuing operations -62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M-37.27%-174.55M
Depreciation and amortization -2.34%4.85M-4.32%4.83M-17.93%19.84M-16.18%4.9M-1.85%4.93M-31.75%4.96M-16.36%5.05M34.64%24.17M-6.63%5.85M-5.75%5.02M
Other non cash items -159.63%-8.18M-765.33%-8.39M-212.63%-14.05M-2,276.26%-4.77M-299.96%-5.16M-188.21%-3.15M-115.89%-969K-11.62%12.47M-95.33%219K-48.43%2.58M
Change In working capital 113.27%10.49M470.33%210.49M-1,075.49%-193.59M-545.02%-203.97M41.34%52.56M-1,066.16%-79.08M505.53%36.91M-26.11%19.85M-271.01%-31.62M299.96%37.19M
-Change in receivables --0--200M-65,673.77%-200M-408,263.27%-200M411,664.71%70M-91,009.09%-70M--0289.44%305K132.03%49K950.00%17K
-Change in prepaid assets -39.98%2.35M-75.51%2.95M1,353.00%23.22M218.05%6.45M-83.76%817K251.69%3.91M161.11%12.04M111.49%1.6M-212.36%-5.46M154.06%5.03M
-Change in payables and accrued expense 180.17%9.28M-62.55%9.44M-492.08%-20.25M70.44%-9.19M-188.32%-24.69M-216.72%-11.58M1,660.27%25.21M-86.23%5.16M-236.50%-31.1M2,040.74%27.96M
-Change in other current liabilities 112.70%40K-154.12%-432K107.23%110K7.80%705K89.29%-110K68.31%-315K-10.39%-170K71.33%-1.52M-44.48%654K-67.54%-1.03M
-Change in other working capital -7.18%-1.18M-730.51%-1.47M-76.69%3.33M-145.76%-1.94M25.68%6.55M-162.43%-1.1M-105.72%-177K63.92%14.3M141.61%4.24M-70.91%5.21M
Cash from discontinued investing activities
Operating cash flow 28.27%-95.58M1,147.32%109.75M47.48%-260.38M15.23%-96.07M62.12%-39.86M6.14%-133.25M106.51%8.8M-191.98%-495.74M-31.72%-113.33M-29.37%-105.22M
Investing cash flow
Cash flow from continuing investing activities -158.50%-126.91M-183.00%-97.8M244.84%374.65M53.60%-81.45M38.74%121.35M486.87%216.92M202.89%117.83M75.02%-258.66M-1,913.91%-175.53M115.48%87.46M
Net PPE purchase and sale 80.11%-707K76.43%-721K74.53%-9.47M88.08%-738K64.80%-2.12M63.08%-3.56M80.07%-3.06M54.49%-37.19M32.58%-6.19M83.76%-6.02M
Net intangibles purchase and sale -----------2.5M--0---1M----------0--0--0
Net investment purchase and sale -156.85%-126.2M-180.30%-97.08M274.57%386.62M52.34%-80.72M33.15%124.47M577.97%221.98M221.91%120.89M76.78%-221.47M-36,361.46%-169.34M117.70%93.48M
Cash from discontinued investing activities
Investing cash flow -158.50%-126.91M-183.00%-97.8M244.84%374.65M53.60%-81.45M38.74%121.35M486.87%216.92M202.89%117.83M75.02%-258.66M-1,913.91%-175.53M115.48%87.46M
Financing cash flow
Cash flow from continuing financing activities -102.78%-466K5,561.25%305.93M62.38%62.66M1,471.39%38.94M-89.70%1.56M61.93%16.77M-49.25%5.4M-84.62%38.59M-60.66%2.48M47.98%15.11M
Net common stock issuance ---1.01M--280.75M3,273.30%32.72M--32.72M--0--0--0-99.55%970K--0----
Proceeds from stock option exercised by employees -96.74%546K366.12%25.19M-20.41%29.94M150.93%6.22M-89.00%1.56M61.93%16.77M-49.25%5.4M-0.15%37.62M-60.66%2.48M38.48%14.14M
Cash from discontinued financing activities
Financing cash flow -102.78%-466K5,561.25%305.93M62.38%62.66M1,471.39%38.94M-89.70%1.56M61.93%16.77M-49.25%5.4M-84.62%38.59M-60.66%2.48M47.98%15.11M
Net cash flow
Beginning cash position 101.88%718.94M79.00%401.07M-76.16%224.06M5.74%539.6M-11.01%456.6M-49.18%356.12M-76.16%224.06M-20.71%939.94M-50.38%510.33M-69.18%513.07M
Current changes in cash -321.97%-222.95M140.76%317.89M124.72%176.94M51.61%-138.59M3,243.38%83.05M153.52%100.44M155.22%132.03M-191.55%-715.8M-223.76%-286.38M99.58%-2.64M
Effect of exchange rate changes -92.86%2K-134.38%-11K191.25%73K-46.96%61K52.00%-48K141.18%28K218.52%32K-627.27%-80K3,733.33%115K-316.67%-100K
End cash Position 8.63%495.99M101.88%718.94M79.00%401.07M79.00%401.07M5.74%539.6M-11.01%456.6M-49.18%356.12M-76.16%224.06M-76.16%224.06M-50.38%510.33M
Free cash flow 30.38%-96.29M1,799.49%109.03M48.90%-272.35M19.00%-96.81M61.37%-42.97M8.76%-138.3M103.81%5.74M-216.55%-532.93M-25.52%-119.52M6.03%-111.24M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --------------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept Gene Editing
Gene Editing
Intraday+0.75%
ARK Portfolio
ARK Portfolio
Intraday+0.14%